# A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

> **NCT00351507** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin

## Key facts

- **NCT ID:** NCT00351507
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00351507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00351507, "A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00351507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*